TREK Diagnostic Systems

TREK Diagnostic Systems is a dedicated microbiology company offering blood culture, identification, and susceptibility technologies to provide cost effective improvements in workflow efficiencies, ergonomics, and test result performance, resulting in better solutions for patient care.

	Order alamarBlue® Click here to learn more about alamarBlue, and to place an order!

	Sign Up: Click here and sign up to receive important updates on TREK products and industry highlights.

	Product Highlights



	Vizion™ System Provides a Whole New Way to Visually Read and Record MICs. See the difference with the Vizion System! more info> Don’t Sacrifice Sensitivity for Stability! alamarBlue® is the only stable resazurin-based product with extended incubation times more info> Introducing the Newest Sensititre® Software Package SWIN Epidemiology Module Take Comprehensive Reporting to a Whole New Level… Intuitive and Educational! more info>

	News Bulletins



	>	TREK Diagnostic Systems Introduces First FDA-Cleared MIC Plate with D-Test and Cefoxitin Screen at the ASM 108th General Meeting
	>	TREK Introduces First FDA-Cleared MIC Plate to Include D-Test and Cefoxitin Screen, Used in MRSA Detection
	>	FDA Clears Doripenem for TREK Sensititre® In Vitro Dry Microbroth Plates used in Clinical-Diagnostic Laboratories
	>	Sensititre® YeastOne® Now Includes Latest Antifungal Agents: Anidulafungin and Micafungin


	Recent Papers



	>	P2135P4 file: Accuracy of Sensititre® ARIS® 2X Microbroth Dilution Panels in Detecting Oxacillin Resistance in Staphylococcus aureus and Coagulase-negative Staphylococci.
	>	U-084 file: Determination of MICs of Nocardia Using the TREK Vizion™ System Compared to Manual Readings.
	>	C-022 file: False-Positive Vancomycin resistant Enterococcus from the BD Phoenix Instrument.
	>	C-215 file: A Multi-Site Evaluation of Caspofungin on Sensititre® YeastOne® Susceptibility System Compared with the CLSI M27 Reference Broth Micro Dilution Plate for Antifungal Susceptibility Testing.
	>	A-010 file: A Multi-Site Study of a Broth Cefoxitin Screen Test Using TREK Sensititre® 18-24 Hour Dried Susceptibility Plates for Predicting the Presence of mecA-mediated Resistance in Staphylococcus aureus.




	Retrospective Analysis Shows VersaTREK Media System Equivalent to BACTEC™ 9240 Additional Benefits Realized by Converting to VersaTREK System A retrospective analysis was performed by three sites that converted to VersaTREK from the BD BACTEC 9240 blood culture system: Rhode Island Hospital (Providence, RI), Miriam Hospital (Providence, RI) and Centrex Laboratories (New Hartford, NY). Positivity and contamination rates were included in the analysis. Over 108,000 total cultures were used in the analysis, and positive and contamination rates were compared between the two systems. Recovery of specific pathogen groups was also assessed. This retrospective study showed VersaTREK’s 2-bottle media system to be equivalent to BD's multi-bottle media system. The positive and contamination rates between VersaTREK and BD were equivalent at all sites. Additional benefits realized by converting to VersaTREK include: cost savings, simplicity in inventory control, ease of use in direct testing, minimizing phlebotomy errors and increasing clinical ease of use with a single media blood culture set for all patients. full paper> Kimberle C. Chapin1, Debra A. Napert1, Jacqueline M. Miller3, and Valerie Whitehead1 1. Rhode Island Hospital (RI) Providence, RI, 2. Miriam Hospital (MH), Providence RI, 3. Centrex Laboratories (CEN), New Hartford, NY

Sitemap Privacy Policy Terms & Conditions